tirzepatide surpass SURPASS-2 (NEJM 2021) was the definitive head-to-head: vs semaglutide 1.0 mg (the maximum approved T2DM dose) in 1,879 patients with type 2 diabetes. All three tirzepatide doses produced superior HbA1c reductions Diabetes Distilled: SURPASS-CVOT – Tirzepatide

Signalen van verzadiging worden minder krachtig

91 In essence, long-acting formulations can achieve sustained therapeutic drug concentrations in the body, whereas short-acting formulations produce transient concentration peaks shortly after injection

If you need stronger appetite control, your doctor may consider GLP-1 medicines such as Semaglutide, Liraglutide, or Dulaglutide

Drug shortages have become commonplace since the start of the pandemic

Results from the SURPASS program's phase 3 trials indicate that tirzepatide, administered weekly in doses of 5mg, 10mg, and 15mg, significantly enhances glycemic control in T2D